Ironwood Pharmaceuticals Investor Relations Material
Latest events
Study Result
Ironwood Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Ironwood Pharmaceuticals Inc
Access all reports
Ironwood Pharmaceuticals, Inc., is a healthcare company that focuses on the development and commercialization of gastrointestinal products. The company develops linaclotide, a guanylate cyclase type-C agonist for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation under the LINZESS name in the United States and under the CONSTELLA name in Europe; and lesinurad for gout.
Key slides for Ironwood Pharmaceuticals Inc
J.P. Morgan 42nd Annual Healthcare Conference 2024
Ironwood Pharmaceuticals Inc
Q4 2023
Ironwood Pharmaceuticals Inc
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States